The Case for a Genetic Predisposition to Serrated Neoplasia in the Colorectum: Hypothesis and Review of the Literature

Joanne Young and Jeremy R. Jass
Molecular Cancer Epidemiology Laboratory, Queensland Institute of Medical Research, Herston, Queensland, Australia and Department of Pathology, McGill University, Montreal, Quebec, Canada

Abstract

In recent years, an alternative pathway of colorectal cancer development has been described in which serrated polyps replace the traditional adenoma as the precursor lesion. Importantly, serrated polyps and a subset of colorectal cancer show largely nonoverlapping mutation profiles to those found in adenomas and the majority of colorectal cancer. These genetic alterations include activating mutation of the BRAF proto-oncogene and widespread gene promoter hypermethylation (CpG island methylator phenotype or CIMP). Up to 15% of colorectal cancer is likely to develop on the basis of a strong genetic predisposition. The two most well-characterized syndromes, familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (Lynch syndrome), both develop via the adenoma-carcinoma pathway and together account for approximately one third of familial colorectal cancer. We have recently described 11 families in which there is evidence that the genetic predisposition to autosomal dominant colorectal cancer is linked to the serrated pathway. This condition, serrated pathway syndrome, and the related condition, hyperplastic polyposis, the presentation of which suggests a recessive mode of inheritance, represent two syndromes in which BRAF mutation and methylation co-occur within serrated precursor lesions. Further, CIMP is observed in the normal colonic mucosa of individuals with hyperplastic polyposis consistent with a field defect in epigenetic regulation. The spectrum of serrated neoplasia may also implicate the apparently sporadic and later onset subset of colorectal cancer with high levels of microsatellite instability. The tendency for these lesions to be multiple, associated with smoking, and to show frequent BRAF mutation and CIMP points to a defect that may result from interactions between the environment and a weakly penetrant genetic alteration. (Cancer Epidemiol Biomarkers Prev 2006;15(10):1778–84)

Introduction

Colorectal cancer has provided a paradigm for the study of molecular pathology in solid tumors. In 1988, Vogelstein et al. (1) developed a molecular model that was based on careful analysis of the mutations occurring within particular developmental stages of colorectal cancer. The progressive accumulation of a critical number of mutations over a period of years, with each genetic change being associated with an evolutionary step in neoplastic transformation, represented the molecular counterpart of the adenoma-carcinoma sequence (2). These steps included initiating mutations of the tumor-suppressor gene APC, activating point mutations in KRAS driving progression, and mutations in TP53 associated with malignant transformation. The model emphasized the central importance of the adenomatous polyp as the precursor lesion for most colorectal cancer, and centered upon a mechanism of tumorigenesis known as chromosomal instability. Publication of the model encouraged an extraordinary expansion of research based on molecular dissection of the developmental pathway to malignancy. Since its introduction, however, new evidence has led to the identification of an alternative and possibly rapidly evolving pathway separate from that proposed by Vogelstein et al. (3, 4). This alternative pathway, in which serrated polyps replace the traditional adenoma as the precursor lesion to colorectal cancer, has become known as the serrated pathway. Importantly, the serrated pathway displays mutation profiles that are largely nonoverlapping with those of the traditional adenoma-carcinoma pathway, including a tight association between widespread DNA methylation (CpG island methylator phenotype or CIMP), and activating mutations in the BRAF proto-oncogene (5-7). In this article, we review the evidence that a subset of familial colorectal cancer evolves via this pathway, based on the frequent occurrence of advanced serrated lesions; BRAF mutation; and CIMP in (a) multicase colorectal cancer families with an autosomal dominant inheritance, (b) rare sibships and individuals with multiple serrated lesions and a recessive mode of inheritance, and (c) high-level microsatellite instability (MSI-H) sporadic colorectal cancer in which synchronous and metachronous lesions are over five times more likely to occur than in the balance of colorectal cancer.

The Serrated Pathway of Colorectal Cancer Development

The concept that almost all colorectal cancers develop within benign adenomatous precursor lesions has been promulgated for decades. Epithelial polypoid lesions in the colorectum are relatively common in Western populations and occur with increasing age. Besides the traditional adenoma, upon which the Vogelstein model is based, another common lesion is the hyperplastic (metaplastic or serrated) polyp, which has been widely dismissed as innocuous. However, a new understanding of the pathology and natural history of hyperplastic polyps has emerged over the past decade (3, 4, 8-23). Serrated polyps encompass the common hyperplastic polyps found most
A Genetic Predisposition to Serrated Neoplasia

It has been estimated that up to 15% of colorectal cancer occurs as part of a strong genetic predisposition. In a significant proportion of these families, the number and distribution of affected individuals implicates a single dominantly inherited mutation (27). A further unknown proportion may be due to subtle genetic influences, which alter the metabolism of extrinsic or endogenous carcinogens (28). In the past decade, it has been estimated that up to 15% of colorectal cancer occurs as part of a strong genetic predisposition, namely familial adenomatous polyposis (Lynch syndrome). Both are inherited as autosomal dominant conditions, in which affected subjects develop early-onset colorectal cancer. However, familial adenomatous polyposis and Lynch syndrome together account for only 2% to 5% of all colorectal cancer, indicating that there are still many families in which the nature of the underlying genetic cause of the family cancers remains to be identified. Familial colorectal cancer also includes recessive modes of inheritance of proximal cancers determined in a population-based family data set (29), mutations in the MYH DNA repair gene (30-32) and a series of non–Lynch syndrome familial colorectal cancer with an autosomal dominant mode of inheritance described by Lindor and colleagues and confirmed by subsequent studies (33-35). Both familial adenomatous polyposis and Lynch syndrome are associated with the traditional adenoma-carcinoma pathway. The possibility of a familial syndrome with origins in the serrated pathway has been considered only recently, although it was first proposed by Jeevaratnam et al. (36) in 1996, and further explored by Jass et al. (37) in 1997.

Table 1. Features of colonic polyp subtypes

<table>
<thead>
<tr>
<th>Polyp name</th>
<th>Alternative terminology</th>
<th>Morphology and significance</th>
<th>Molecular features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenoma</td>
<td>Adenomatous polyp</td>
<td>Neoplastic polyp with malignant potential</td>
<td>BRAF mutation and CIMP rare</td>
</tr>
<tr>
<td>Serrated polyp</td>
<td>Various (see below)</td>
<td>General term for all colorectal polyps with glandular serration</td>
<td></td>
</tr>
<tr>
<td>Hyperplastic polyp,</td>
<td>Type 1 hyperplastic polyp</td>
<td>Subtype of hyperplastic polyp with conspicuous goblet cells and showing the least morphologic deviation from normal; described as goblet-cell rich type. Found predominantly in the distal colon</td>
<td>Frequent KRAS mutation (54%; ref. 89)</td>
</tr>
<tr>
<td>goblet type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperplastic polyp,</td>
<td>Type 2 hyperplastic polyp</td>
<td>Variant of hyperplastic polyp in which columnar cells have mucin-filled vesicles within the apical cytoplasm and goblet cells are relatively inconspicuous</td>
<td>Frequent BRAF mutation (76%) and CIMP (68%; ref. 89)</td>
</tr>
<tr>
<td>microvesicular type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSA</td>
<td>Sessile serrated polyp. Serrated polyp with atypical proliferation</td>
<td>Advanced type of serrated polyp with abnormalities of architecture and proliferation but lacking the classic features of epithelial dysplasia (intraepithelial neoplasia)</td>
<td>Frequent BRAF mutation (75-82%) and CIMP (92%; refs. 5, 89)</td>
</tr>
<tr>
<td>MP</td>
<td>Admixed polyp</td>
<td>Rare serrated polyp that includes two separate components. One component is usually nondysplastic (usually SSA) whereas the second dysplastic component is either traditional adenoma or serrated adenoma; partly hyperplastic polyp and partly adenoma. Polyps with mixtures of adenoma and SA have also been described as mixed polyps</td>
<td>Frequent BRAF mutation, especially when SSA forms part of the lesion (89%; ref. 5)</td>
</tr>
<tr>
<td>SA</td>
<td>(a) Mixed hyperplastic adenomatous polyp. (b) Atypical hyperplastic polyp. (c) Traditional SA</td>
<td>Relatively rare neoplastic polyp having a serrated architecture reminiscent of hyperplastic polyp but with unequivocal traditional adenomatous dysplasia. Comprises &lt;5% of serrated polyps</td>
<td>Marked molecular heterogeneity. Overlapping molecular pathways. May have either KRAS or BRAF mutation or and features of the adenoma-carcinoma pathway</td>
</tr>
</tbody>
</table>

NOTE: Data are adapted from ref. 16.
1990s, HPP was acknowledged as a condition carrying an increased risk for malignant transformation. Individuals with HPP present with synchronous cancers of the colorectum in approximately one half of the cases (44, 48). Because HPP is a relatively rare condition and examples associated with colorectal cancer are likely to present for symptomatic reasons, it is difficult to determine the overall proportion of cases that will develop colorectal cancer. However, cases with large, atypical, and dysplastic polyps appear to be at the highest risk for presenting with a synchronous colorectal cancer (44). HPP is a relatively late-onset disorder, usually diagnosed in the fifth to the seventh decades of life, although it can occur earlier (49, 50). Polyp numbers range from 5 to well over 100, with most cases having between 40 and 100 lesions (51). A characteristic feature of HPP is the diverse range of polyp types, ranging from diminutive hyperplastic polyps to larger SSA, SA, and MP as well as traditional adenomas (52-54).

Recently, Burt and Jass (55) developed a working definition of HPP, namely (a) at least five proximal hyperplastic polyps two of which are >10 mm in diameter, or (b) any number of HPs proximal to the sigmoid colon in an individual with a first-degree relative with HPP, or (c) >20 hyperplastic polyps distributed throughout the colon.

It was initially thought that HPP was not associated with a family history of HPP or colorectal cancer in first-degree relatives. However, HPP may sometimes occur in several members of the same family (36, 37, 45), whereas colorectal cancer occurs in 27% of relatives of cases with HPP (45). Fourteen patients studied in a Portuguese series reported 57% of first-degree relatives with polyps and 33% with a family history of colorectal cancer (51). In contrast, a study of 15 cases of HPP from Utah found no evidence of HPP or any spectrum cancers in relatives, although it was not clear whether this study had excluded cases with satellite lesions in the distal colon (56). The rare existence of sibships, and consanguineous families with HPP (57) suggests a recessively inherited basis for the initiation of this condition.

Widespread DNA methylation (CIMP) and BRAF mutation have been reported in the serrated neoplasms of patients with HPP (58, 59), reflecting the signature changes of the serrated pathway observed in their sporadic counterparts (5, 7). The presence of a BRAF mutation in a serrated lesion from a patient with multiple hyperplastic polyps was at least five times more likely to be associated with a second BRAF mutation–bearing lesion than if the index lesion did not harbor such a mutation (59). The concept of a field defect in colonic mucosa is well shown in a penetrant genetic predisposition such as familial adenomatous polyposis. Similarly, in HPP, hypermethylation of multiple gene promoters is not confined to the neoplastic tissues. Minoo and colleagues (60-62) have recently shown a significant difference in the number of methylated markers seen in apparently normal mucosa of HPP when compared with cases with sporadic serrated lesions (85-90% versus 13%), further supporting the hypothesis that HPP is associated with an underlying and genetically determined field change. Two examples of families in which HPP is present are shown in Fig. 2A.

Serrated Pathway Syndrome

Evidence also exists for an autosomal dominant predisposition to serrated neoplasia. We have recently described 11 MSI-variable (MSI-V) colorectal cancer families in which there are...
interesting clinical, morphologic, and molecular parallels with the serrated pathway (63). These features include a relatively high frequency of \( \text{BRAF} \) mutation, increased levels of methylation in the CpG island marker \( \text{MINT31} \) (64), a background of advanced serrated polyps, female preponderance, proximal predilection, and increased glandular serration within colorectal cancers. The families comprise affected individuals across several generations with 6 of 11 families fulfilling the Amsterdam I criteria. The families represent a novel syndrome of colorectal cancer originating through the serrated pathway of tumorigenesis. We have called this condition serrated pathway syndrome (SPS). Two examples of SPS families are shown in Fig. 2B.

Polyps and cancers from SPS families showed \( \text{BRAF} \) mutations at levels commensurate with that seen in individuals with HPP. \( \text{BRAF} \) mutations were found in 14 of 20 (70%) cancers and in 12 of 19 (63%) polyps in SPS families. In a series of HPP cases published recently, 45 of 68 (66%) polyps showed \( \text{BRAF} \) mutation (59). This compares with 15% seen in unselected colorectal cancers. In contrast, several studies have suggested that \( \text{BRAF} \) mutation is very rare in Lynch syndrome tumors, further delineating SPS as a separate entity (65, 66). Of 13 serrated polyps available for study in SPS families, five (39%) were “advanced” serrated polyps (SSA, SA, and MP). This level of advanced serrated lesions is ~10 times more frequent than that seen in a cohort of individuals attending an outpatient gastroenterology clinic. In that particular study, 65 of 1,436 (4.5%) polyps removed by colonoscopy were advanced serrated lesions (67). Interestingly, 2 of 42 subjects (4.8%) in the 11 SPS families met the criteria for the rare condition of HPP, suggesting that gene dosage may play a role in the serrated neoplasia phenotype. A summary of conditions with features of serrated neoplasia is given in Table 2.

### The Nature of a Genetic Predisposition

Clues to the nature of the genetic change underlying these disorders can be gleaned from examination of molecular and pathology phenotypes. \( \text{BRAF} \) mutation is a frequent although not universal finding in SPS and HPP, and is always present as a somatic mutation. Although the underlying genetic causation of SPS families and HPP individuals is currently unknown, a reasonable explanation would implicate a genetic predisposition to (either directly or indirectly) hypermethylate multiple gene promoters. Evidence that a genetic mechanism could

### Table 2. Features of colorectal cancer predispositions involving \( \text{BRAF} \) mutation and hypermethylation

<table>
<thead>
<tr>
<th>Features</th>
<th>HPP</th>
<th>SPS</th>
<th>Sporadic CIMP CRC</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSI status of CRC</td>
<td>Predominantly MSS with occasional MSI-L and MSI-H (44, 45, 91)</td>
<td>Predominantly MSS with occasional MSI-L and MSI-H CRC (63)</td>
<td>At least 50% are MSI-H and the remainder are MSI-L or MSS (93)</td>
</tr>
<tr>
<td>Precursor lesions</td>
<td>Multiple serrated polyps and a lesser number of adenomas (51)</td>
<td>Sparse serrated polyps and adenomas present. Occasional individual has HPP</td>
<td>SSA (12). May present with synchronous serrated polyps and adenomas</td>
</tr>
<tr>
<td>Sex ratio and age of onset</td>
<td>Equal sex ratios, 54 y</td>
<td>Female preponderance, 58 y</td>
<td>Female preponderance, 74 y</td>
</tr>
<tr>
<td>Family history</td>
<td>Occasional first-degree relative with colorectal cancer (51), rare sibships, suggestive of codominant or recessive inheritance</td>
<td>Multicase colorectal cancer family, Amsterdam-like configuration</td>
<td>No family history</td>
</tr>
<tr>
<td>( \text{BRAF} ) mutation</td>
<td>Up to 66% of lesions (59)</td>
<td>Up to 70% of lesions</td>
<td>In virtually all MSI-H CRC and up to 75% of the remainder</td>
</tr>
<tr>
<td>Methylation</td>
<td>CIMP is common (58, 59)</td>
<td>Methylation of ( \text{MINT31} ) 80%. Methylation of ( \text{MLH1} ) in all MSI-H cases</td>
<td>Widespread CIMP</td>
</tr>
</tbody>
</table>

Abbreviation: CRC, colorectal cancer.

---

*Figure 2. A*, two HPP pedigrees showing possible recessive inheritance and a single individual and a sibship respectively with multiple serrated polyps (dotted symbols). *B*, two multicase colorectal cancer families showing affected individuals with colorectal cancer (filled symbols) and advanced or multiple serrated polyps (dotted symbols), and their ages of onset.
underlie concordant hypermethylation and therefore serrated neoplasia has emerged from studies that have considered family history of cancer in association with CIMP. In a study from Frazier et al. (64), patients with CIMP cancers were 14 times more likely to have a family history of cancer than patients with cancers that did not show extensive DNA methylation. Further, concordant methylation and BRAF mutations are observed in the multiple lesions from individuals with HPP. Finally, reports from Samowitz and colleagues found a significant relationship between BRAF mutation and family history of colonic neoplasia in a large unselected study of over 800 individuals. Given the synergy between BRAF mutation and CIMP (7), this constitutes further evidence that a predisposition to hypermethylated gene promoters may be present in the population and could underlie novel syndromes of familial colorectal cancer (68, 69). Although there has been a single report to the contrary (70), the clinical rather than molecular ascertainment of Lynch syndrome families in this study is likely to have screened out SPS families as a consequence.

In imputing an epigenetic control defect, rather than an epimutation that targets only one promoter in the germ line (71), it might be assumed that CpG islands would undergo stochastic methylation events and would all be equally liable to do so. However, in CIMP colorectal cancer, some CpG islands are less likely to undergo hypermethylation than others. MLH1 is frequently methylated in CIMP colorectal cancer, whereas both MSH2 and PMS2 are rarely methylated, despite the fact that these genes play essential roles in mismatch repair, have equally well-defined promoter CpG islands, and are involved in germ line mutations associated with Lynch syndrome. Conversely, CIMP affects the promoters of a wide variety of genes with no definitive role in colon tumor development, suggesting that not all de novo events are subject to growth selection (72). Further, evidence has been presented that particular sequence motifs are significantly overrepresented among promoters vulnerable to CIMP, implicating an underlying directive mechanism (72-74). Hence, control defects due to alterations in epigenetic regulators will target a subset of vulnerable loci, rather than all loci equally (7, 72, 75).

Age-related hypermethylation has been observed in normal colonic mucosa (76) and has been postulated as a potential marker for field cancerization or a field defect (77), an area of abnormal tissue that has the potential to develop into a cancer (78). The area may appear essentially normal or may contain multiple discrete neoplastic lesions. It has previously been suggested that aberrant DNA methylation of tumor-suppressor genes may occur secondary to a genetic predisposition or to a field cancerization effect in the colon and may be useful as a molecular marker of colorectal cancer risk (79). Because sporadic MSI-H colorectal cancers are more likely to be multiple (80, 81) and of a serrated phenotype, it is also likely that subjects predisposed to MSI-H sporadic colorectal cancer have a field defect involving widespread hypermethylation. Consistent with this proposal, DNA hypermethylation has been reported more frequently from the normal colonic mucosa of patients bearing CIMP and sporadic MSI-H colorectal cancer (82, 83).

**Genetic and Environmental Modifiers**

Many cancers result from the combined effects of an inherited susceptibility and environmental influences. Although there is evidence for a genetic predisposition to DNA methylation, it is likely that lifestyle factors and genetic modifiers will also play a role. The magnitude of the contribution of lifestyle factors such as physical activity, body mass index, or use of aspirin and/or nonsteroidal anti-inflammatory drugs in the etiology of sporadic MSI-H colorectal cancers is currently not precisely fixed. However, studies of cigarette smoking and colorectal cancer have produced positive associations. Using data from a population-based, case-control study of colon cancer with case subjects ages between 30 and 79 years of age, Slattery et al. (84) found that cases with MSI-H colorectal cancer were more likely to smoke ≥20 cigarettes per day than case subjects with microsatellite stable (MSS) cancers. The association between MSI-H colorectal cancer and cigarette smoking was strongest among case subjects who started to smoke at a young age, smoked for ≥35 years, and were either current smokers or had stopped <15 years before diagnosis. A statistically significant linear trend of increased risk of MSI-H colorectal cancer was observed with increasing amount smoked. The study suggested that the attributable risk of smoking in MSI-related colorectal cancer is 21%. This has been confirmed by the finding that MSI colorectal cancer are more likely to arise in current smokers (85), and that smoking is associated with an increased risk of developing serrated lesions in individuals with a particular genotype (86).

**Advances in Gastrointestinal Pathology and Implications for Surveillance**

The role of serrated (hyperplastic) polyps in colorectal cancer development has gained increasing recognition in recent years due to evidence that a subset of these lesions are the likely precursors of sporadic MSI-H colorectal cancer (25). In addition, there is a growing awareness of the importance of screening in individuals with multiple serrated polyps (22, 51, 87), especially if dysplasia is evident (25) due to their increased risk of developing colorectal cancer. These insights

---

**Figure 3.** Three settings exemplify serrated neoplasia. A. HPP where numerous serrated polyps develop, and in which synchronous cancers may be present. B. SPS, which is a multicase and multigeneneration colorectal cancer predisposition associated with advanced serrated polyps. C. Sporadic CIMP cancers where no evidence of family history is apparent but synchronous and metachronous lesions may be present. These three settings share molecular pathology phenotypes that suggest development from an epigenetic regulatory defect inherited as a recessive condition, an autosomal dominant disorder and a polymorphic variant, respectively.
have highlighted the need for defining the morphologic criteria that characterize serrated polyps with increased malignant potential, notably SSA, and detailed guidelines have been proposed by several authors (12, 21, 25, 88, 89). However, lack of prospective studies, underreporting, and confusing terminology will inevitably delay the widespread dissemination and acceptance of these insights within the arena of clinical practice. Colorectal cancer mortality has been decreasing slowly in Western countries during the last decade, and the probable explanation for this is increased surveillance. Colorectal cancer has a particular feature that makes it amenable to prevention in that it is preceded by a premalignant polyp that can be removed safely. The inclusion among the polyps requiring surveillance and removal should contribute to the prevention of colorectal cancers with CIMP (90). Importantly, the discovery of the germ line alteration underlying SPS and HPP will identify the individuals and their families who are most at risk for the development of serrated neoplasia.

Conclusion and Hypothesis

Based on the co-occurrence of Braf mutation, CIMP, and serrated neoplasia, and the segregation of these features in families with recessive and dominant modes of inheritance, we propose a model that implicates a genetic predisposition to (directly or indirectly) hypermethylate gene promoters as the fundamental defect underlying SPS and HPP (Fig. 3). We hypothesize that a germ line sequence alteration in a gene or (conventional)-type colorectal polyps: molecular-genetic pathways, and implications for classification. Am J Clin Pathol 2006;125:146–53.


The Case for a Genetic Predisposition to Serrated Neoplasia in the Colorectum: Hypothesis and Review of the Literature

Joanne Young and Jeremy R. Jass


Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/15/10/1778

Cited articles
This article cites 91 articles, 27 of which you can access for free at:
http://cebp.aacrjournals.org/content/15/10/1778.full.html#ref-list-1

Citing articles
This article has been cited by 11 HighWire-hosted articles. Access the articles at:
/content/15/10/1778.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.